PATENT CLAIM ANALYSIS

Application Number: 16037309
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "367000"]

Abstract:
The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

Claim (Index 62):
The process according to  claim 61 , wherein R 1  is H or C 1 -C 6  haloalkyl.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.53247
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13055333', '14817455', '14048768', '13060477', '14464251']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.837065048819192
- 35 USC 102 Novelty (BERT): 0.6340508453142251
- Combined Prediction Score: 0.8167636284686952
- Mean Citation Score: 593.934828
- Max Citation Score: 659.6312
- Similarity Product: 521.0452436986924

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test